SE0302853D0 - Chemical compounds - Google Patents

Chemical compounds

Info

Publication number
SE0302853D0
SE0302853D0 SE0302853A SE0302853A SE0302853D0 SE 0302853 D0 SE0302853 D0 SE 0302853D0 SE 0302853 A SE0302853 A SE 0302853A SE 0302853 A SE0302853 A SE 0302853A SE 0302853 D0 SE0302853 D0 SE 0302853D0
Authority
SE
Sweden
Prior art keywords
formula
chemical compounds
compound
carboxypeptidase
prophylaxis
Prior art date
Application number
SE0302853A
Other languages
English (en)
Swedish (sv)
Inventor
Magnus Polla
Petter Bjoerquist
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29580155&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SE0302853(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0302853A priority Critical patent/SE0302853D0/xx
Publication of SE0302853D0 publication Critical patent/SE0302853D0/xx
Priority to MYPI20044426A priority patent/MY143363A/en
Priority to RU2006117821/04A priority patent/RU2365594C2/ru
Priority to AU2004283643A priority patent/AU2004283643B2/en
Priority to BRPI0415964-0A priority patent/BRPI0415964A/pt
Priority to JP2006537936A priority patent/JP2008501622A/ja
Priority to EP04793868A priority patent/EP1689424A1/en
Priority to CNA2004800390596A priority patent/CN1897963A/zh
Priority to CA002543630A priority patent/CA2543630A1/en
Priority to US10/578,022 priority patent/US20080039376A1/en
Priority to PCT/SE2004/001568 priority patent/WO2005039617A1/en
Priority to KR1020067010392A priority patent/KR20060132596A/ko
Priority to UY28585A priority patent/UY28585A1/es
Priority to UAA200604776A priority patent/UA85199C2/ru
Priority to TW093132865A priority patent/TW200524576A/zh
Priority to ARP040104004A priority patent/AR046612A1/es
Priority to SA05250463A priority patent/SA05250463B1/ar
Priority to IL175198A priority patent/IL175198A0/en
Priority to ZA200603355A priority patent/ZA200603355B/en
Priority to NO20061999A priority patent/NO20061999L/no
Priority to IS8471A priority patent/IS8471A/is
Priority to CO06049388A priority patent/CO5690614A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
SE0302853A 2003-10-29 2003-10-29 Chemical compounds SE0302853D0 (sv)

Priority Applications (22)

Application Number Priority Date Filing Date Title
SE0302853A SE0302853D0 (sv) 2003-10-29 2003-10-29 Chemical compounds
MYPI20044426A MY143363A (en) 2003-10-29 2004-10-27 Use of cyclic anabaenopeptin-type peptides for the treatment of a condition wherein inhibition of carboxypeptidase u is beneficial, novel anabaenopeptin derivatives and intermediates thereof
UY28585A UY28585A1 (es) 2003-10-29 2004-10-28 Compuestos químicos
UAA200604776A UA85199C2 (ru) 2003-10-29 2004-10-28 Применение циклических пептидов типа анабенопептина для лечения состояний, при которых показано угнетение карбоксипептидазы u, производные анабенопептина и их промежуточные соединения
US10/578,022 US20080039376A1 (en) 2003-10-29 2004-10-28 Use of Cyclic Anabaenopeptin-type Peptides for the Treatment of a Condition Wherein Inhibition of Carboxypeptidase U is Beneficial, Novel Anabaenopeptin Derivatives and Intermediates Thereof
KR1020067010392A KR20060132596A (ko) 2003-10-29 2004-10-28 카르복시펩티다제 ｕ의 억제가 유리한 증상의 치료를 위한아나베노펩틴-유형 펩티드의 용도, 신규한 아나베노펩틴유도체 및 이것의 중간체
BRPI0415964-0A BRPI0415964A (pt) 2003-10-29 2004-10-28 uso de um composto, composto, formulação farmacêutica, e, processo para preparar um composto
JP2006537936A JP2008501622A (ja) 2003-10-29 2004-10-28 カルボキシペプチダーゼｕの阻害が有用な疾患を治療するための環状アナベノペプチン型のペプチドの使用、新規アナベノペプチン誘導体、および、それらの中間体
EP04793868A EP1689424A1 (en) 2003-10-29 2004-10-28 Use of cyclic anabaenopeptin-type peptides for the treatment of a condition wherein inhibition of carboxypeptidase u is beneficial, novel anabaenopeptin derivatives and intermediates thereof
CNA2004800390596A CN1897963A (zh) 2003-10-29 2004-10-28 环形鱼腥藻肽－型肽治疗其中抑制羧肽酶u对其有益的病症的用途,新型鱼腥藻肽衍生物及其中间体
CA002543630A CA2543630A1 (en) 2003-10-29 2004-10-28 Use of cyclic anabaenopeptin-type peptides for the treatment of a condition wherein inhibition of carboxypeptidase u is beneficial, novel anabaenopeptin derivatives and intermediates thereof
RU2006117821/04A RU2365594C2 (ru) 2003-10-29 2004-10-28 Применение циклических пептидов анабенопептинового типа для лечения состояния, при котором полезно ингибирование карбоксипептидазы u, новые анабенопептиновые производные и их промежуточные соединения
PCT/SE2004/001568 WO2005039617A1 (en) 2003-10-29 2004-10-28 Use of cyclic anabaenopeptin-type peptides for the treatment of a condition wherein inhibition of carboxypeptidase u is beneficial, novel anabaenopeptin derivatives and intermediates thereof
AU2004283643A AU2004283643B2 (en) 2003-10-29 2004-10-28 Use of cyclic anabaenopeptin-type peptides for the treatment of a condition wherein inhibition of carboxypeptidase U is beneficial, novel anabaenopeptin derivatives and intermediates thereof
TW093132865A TW200524576A (en) 2003-10-29 2004-10-29 Chemical compounds
ARP040104004A AR046612A1 (es) 2003-10-29 2004-11-01 Peptidos ciclicos tipo anabaenopeptina, su uso y composiciones farmaceuticas
SA05250463A SA05250463B1 (ar) 2003-10-29 2005-01-29 مشتقات انابينوبيبتين واستخدامها في علاج حالات يفيد فيها تثبيط إنزيم كربوكسي بيبتيداز u
IL175198A IL175198A0 (en) 2003-10-29 2006-04-25 Use of cyclic anabaenopeptin-type peptides for the treatment of a condition wherein inhibition of carboxypeptidase u is beneficial, novel anabaenopeptin derivatives and intermediates thereof
ZA200603355A ZA200603355B (en) 2003-10-29 2006-04-26 Use of cyclic anabaenopeptin-type peptides for the treatment of a condition wherein inhibition of carboxypeptidase U is beneficial, novel anabaenopeptin derivatives and intermediates thereof
NO20061999A NO20061999L (no) 2003-10-29 2006-05-04 Anvendelse av syliske anabaenopeptin-type peptider for behandling av en tilstand hvor inhibering av karboksypeptidase U er fordelaktig, nye anabaenopeptin-derivater og mellomprodukter derav
IS8471A IS8471A (is) 2003-10-29 2006-05-16 Notkun á hringtengdum peptíðum af anabaenópeptíngerð til að meðhöndla ástand þar sem tálmun á karboxýpeptíðasa U er gagnleg, nýjar anabaenópeptínafleiður og milliefni þeirra
CO06049388A CO5690614A2 (es) 2003-10-29 2006-05-23 Uso de peptidos ciclicos tipo anabaenopeptina para el tratamiento de una enfermedad en donde es benefica la inhibicion de carboxipeptidasa u derivados novedosos de anabaenopeptina y sus intermedios

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0302853A SE0302853D0 (sv) 2003-10-29 2003-10-29 Chemical compounds

Publications (1)

Publication Number Publication Date
SE0302853D0 true SE0302853D0 (sv) 2003-10-29

Family

ID=29580155

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0302853A SE0302853D0 (sv) 2003-10-29 2003-10-29 Chemical compounds

Country Status (22)

Country Link
US (1) US20080039376A1 (xx)
EP (1) EP1689424A1 (xx)
JP (1) JP2008501622A (xx)
KR (1) KR20060132596A (xx)
CN (1) CN1897963A (xx)
AR (1) AR046612A1 (xx)
AU (1) AU2004283643B2 (xx)
BR (1) BRPI0415964A (xx)
CA (1) CA2543630A1 (xx)
CO (1) CO5690614A2 (xx)
IL (1) IL175198A0 (xx)
IS (1) IS8471A (xx)
MY (1) MY143363A (xx)
NO (1) NO20061999L (xx)
RU (1) RU2365594C2 (xx)
SA (1) SA05250463B1 (xx)
SE (1) SE0302853D0 (xx)
TW (1) TW200524576A (xx)
UA (1) UA85199C2 (xx)
UY (1) UY28585A1 (xx)
WO (1) WO2005039617A1 (xx)
ZA (1) ZA200603355B (xx)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10656719B2 (en) 2014-09-30 2020-05-19 Apple Inc. Dynamic input surface for electronic devices
TWI628569B (zh) 2015-09-30 2018-07-01 蘋果公司 具有適應性輸入列之鍵盤
PL3464336T3 (pl) 2016-06-01 2022-05-16 Athira Pharma, Inc. Związki
US10732743B2 (en) 2017-07-18 2020-08-04 Apple Inc. Concealable input region for an electronic device having microperforations
WO2019040973A1 (en) 2017-09-01 2019-03-07 Alsonex Pty Ltd METHOD FOR SOLID PHASE SYNTHESIS OF CYCLIC PENTAPEPTIDES

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9524630D0 (en) * 1994-12-24 1996-01-31 Zeneca Ltd Chemical compounds
WO2002014285A1 (en) * 2000-08-17 2002-02-21 Pfizer Limited Substituted imidazoles as tafia inhibitors

Also Published As

Publication number Publication date
CO5690614A2 (es) 2006-10-31
AR046612A1 (es) 2005-12-14
IS8471A (is) 2006-05-16
WO2005039617A1 (en) 2005-05-06
UA85199C2 (ru) 2009-01-12
US20080039376A1 (en) 2008-02-14
SA05250463A (ar) 2005-12-03
RU2006117821A (ru) 2007-12-10
BRPI0415964A (pt) 2007-01-23
IL175198A0 (en) 2006-09-05
AU2004283643B2 (en) 2008-07-10
RU2365594C2 (ru) 2009-08-27
CN1897963A (zh) 2007-01-17
EP1689424A1 (en) 2006-08-16
SA05250463B1 (ar) 2009-02-07
NO20061999L (no) 2006-07-27
MY143363A (en) 2011-04-29
UY28585A1 (es) 2005-05-31
KR20060132596A (ko) 2006-12-21
CA2543630A1 (en) 2005-05-06
TW200524576A (en) 2005-08-01
AU2004283643A1 (en) 2005-05-06
ZA200603355B (en) 2007-07-25
JP2008501622A (ja) 2008-01-24

Similar Documents

Publication Publication Date Title
UY28014A1 (es) Compuestos quimicos
GB0111523D0 (en) Chemical compounds
NO20051695L (no) Nye spirokondenserte kinazolinoner og deres anvendelse som fosfodiestereaseinbibitorer
HRP20090159T1 (en) Use of glucosidase inhibitors for therapy of mucovisidosis
WO2004037789A3 (en) Methylene urea derivatives as raf-kinase inhibitors
BR0309343A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas
BR0309342A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas
IL173377A0 (en) Compounds for the treatment of metabolic disorders
SE0301232D0 (sv) Novel use
NO331012B1 (no) N-sulfonyl-4-metylenamino-3-hydroksy-2-pyridoner som antimikrobielle midler
SE0203304D0 (sv) Novel Coumpounds
UA96969C2 (xx) Ациламінопіразоли як fgfr інгібітори[ациламинопиразолы как fgfr ингибиторы
MXPA04006041A (es) Antivirales de piridoquinoxalina.
WO2003101382A3 (en) Compounds useful in the treatment of anthrax and inhibiting lethal factor
SG162614A1 (en) Bicyclic 6-alkylidene-penems as beta-lactamases inhibitors
SE0302853D0 (sv) Chemical compounds
AU2001246999A1 (en) New neurokinin antagonists for use as medicaments
GB0212410D0 (en) Organic compounds
ATE447953T1 (de) Pharmazeutische zusammensetzungen zur behandlung von leishmaniasis
AU2001244999A1 (en) Naphthamide neurokinin antagonists for use as medicaments
SE0402591D0 (sv) Novel use
DE50308492D1 (de) Verbindungen, die faktor xa-aktiv t inhibieren
MXPA05003909A (es) Compuestos de benzopiranona, composiciones de los mismos, y metodos para el tratamiento o prevencion del cancer.
AU2003216965A1 (en) Compounds, particularly of urea derivatives or ester derivatives of haloacetamidobenzoic acid and use thereof for the treatment of parasitic diseases
SE0102640D0 (sv) Novel compounds